Swedbank AB Has $22.77 Million Stock Position in Insulet Corporation $PODD

Key Points

• Swedbank AB increased its stake in Insulet Corporation by 49.8% during Q2, now owning 72,488 shares valued at approximately $22.77 million.
• Insulet received several positive analyst upgrades, with JPMorgan raising its target price to $415 and a consensus rating of "Moderate Buy" based on 16 Buy ratings.
• Insulet reported $1.17 earnings per share for the last quarter, significantly beating expectations, with revenue up 32.9% year-over-year.

Swedbank AB grew its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 49.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 72,488 shares of the medical instruments supplier's stock after purchasing an additional 24,100 shares during the quarter. Swedbank AB owned about 0.10% of Insulet worth $22,774,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in PODD. Public Employees Retirement System of Ohio increased its holdings in shares of Insulet by 29.9% during the 4th quarter. Public Employees Retirement System of Ohio now owns 33,063 shares of the medical instruments supplier's stock worth $8,632,000 after acquiring an additional 7,613 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Insulet during the 4th quarter valued at $439,000. Toronto Dominion Bank lifted its position in shares of Insulet by 55.2% during the 4th quarter. Toronto Dominion Bank now owns 36,486 shares of the medical instruments supplier's stock valued at $9,526,000 after acquiring an additional 12,984 shares during the period. Peak Retirement Planning Inc. bought a new stake in shares of Insulet during the 4th quarter worth $1,063,000. Finally, Mackenzie Financial Corp lifted its position in shares of Insulet by 7.0% during the 4th quarter. Mackenzie Financial Corp now owns 7,561 shares of the medical instruments supplier's stock worth $1,974,000 after buying an additional 493 shares during the last quarter.

Analyst Ratings Changes

PODD has been the subject of a number of recent research reports. JPMorgan Chase & Co. upped their target price on Insulet from $340.00 to $415.00 and gave the stock an "overweight" rating in a report on Friday, September 12th. Wall Street Zen upgraded Insulet from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Canaccord Genuity Group increased their price target on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Jefferies Financial Group restated a "buy" rating on shares of Insulet in a report on Thursday, August 7th. Finally, The Goldman Sachs Group assumed coverage on Insulet in a research report on Friday, May 30th. They set a "buy" rating and a $380.00 price target for the company. Sixteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Insulet has a consensus rating of "Moderate Buy" and a consensus target price of $343.06.

Insider Buying and Selling

In related news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company's stock, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by company insiders.

Insulet Stock Performance

Insulet stock opened at $330.84 on Friday. The company has a market capitalization of $23.29 billion, a PE ratio of 100.56, a P/E/G ratio of 2.75 and a beta of 1.36. Insulet Corporation has a fifty-two week low of $225.37 and a fifty-two week high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The company has a 50 day moving average price of $315.14 and a 200-day moving average price of $294.26.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same period in the prior year, the firm earned $0.55 EPS. The firm's revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.